83 related articles for article (PubMed ID: 22613828)
1. [Influence of clinical and biographical factors on the delay in starting adjuvant chemotherapy treatment among breast cancer patients].
Baena-Cañada JM; Rosado-Varela P; Estalella-Mendoza S; Expósito-Álvarez I; González-Guerrero M; Benítez-Rodríguez E
Med Clin (Barc); 2013 May; 140(10):444-8. PubMed ID: 22613828
[TBL] [Abstract][Full Text] [Related]
2. Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer.
Lohrisch C; Paltiel C; Gelmon K; Speers C; Taylor S; Barnett J; Olivotto IA
J Clin Oncol; 2006 Oct; 24(30):4888-94. PubMed ID: 17015884
[TBL] [Abstract][Full Text] [Related]
3. Oncoplastic breast conservation does not lead to a delay in the commencement of adjuvant chemotherapy in breast cancer patients.
Khan J; Barrett S; Forte C; Stallard S; Weiler-Mithoff E; Doughty JC; Romics L
Eur J Surg Oncol; 2013 Aug; 39(8):887-91. PubMed ID: 23746877
[TBL] [Abstract][Full Text] [Related]
4. [Clinical analysis of resectable breast cancer: a report of 6 263 cases].
Yang MT; Rong TH; Huang ZF; Zeng CG; Long H; Fu JH; Lin P; Wang X; Wang SY; Wang X; Tang J
Ai Zheng; 2005 Mar; 24(3):327-31. PubMed ID: 15757535
[TBL] [Abstract][Full Text] [Related]
5. Use of health-care services during chemotherapy for breast cancer.
Baena-Cañada JM; Estalella-Mendoza S; Rosado-Varela P; Expósito-Álvarez I; González-Guerrero M; Díaz-Blanco MC; Cortés-Carmona C; Ramírez-Daffós P; Arriola-Arellano E; Rueda-Ramos A; Solana-Grimaldi L; Benítez-Rodríguez E
Eur J Cancer; 2012 Dec; 48(18):3328-34. PubMed ID: 22683169
[TBL] [Abstract][Full Text] [Related]
6. Delay of adjuvant chemotherapy initiation following breast cancer surgery among elderly women.
Hershman DL; Wang X; McBride R; Jacobson JS; Grann VR; Neugut AI
Breast Cancer Res Treat; 2006 Oct; 99(3):313-21. PubMed ID: 16583264
[TBL] [Abstract][Full Text] [Related]
7. Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial.
Del Mastro L; De Placido S; Bruzzi P; De Laurentiis M; Boni C; Cavazzini G; Durando A; Turletti A; Nisticò C; Valle E; Garrone O; Puglisi F; Montemurro F; Barni S; Ardizzoni A; Gamucci T; Colantuoni G; Giuliano M; Gravina A; Papaldo P; Bighin C; Bisagni G; Forestieri V; Cognetti F;
Lancet; 2015 May; 385(9980):1863-72. PubMed ID: 25740286
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant chemotherapy in elderly patients with early breast cancer. Impact of age and comprehensive geriatric assessment on tumor board proposals.
Barthélémy P; Heitz D; Mathelin C; Polesi H; Asmane I; Litique V; Rob L; Bergerat JP; Kurtz JE
Crit Rev Oncol Hematol; 2011 Aug; 79(2):196-204. PubMed ID: 20655243
[TBL] [Abstract][Full Text] [Related]
9. Early response to neo-adjuvant chemotherapy in carcinoma of the breast predicts both successful breast-conserving surgery and decreased risk of ipsilateral breast tumor recurrence.
Ishitobi M; Komoike Y; Motomura K; Koyama H; Inaji H
Breast J; 2010; 16(1):9-13. PubMed ID: 19929889
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial.
Coleman R; Cameron D; Dodwell D; Bell R; Wilson C; Rathbone E; Keane M; Gil M; Burkinshaw R; Grieve R; Barrett-Lee P; Ritchie D; Liversedge V; Hinsley S; Marshall H;
Lancet Oncol; 2014 Aug; 15(9):997-1006. PubMed ID: 25035292
[TBL] [Abstract][Full Text] [Related]
11. Incremental risk associated with contralateral prophylactic mastectomy and the effect on adjuvant therapy.
Eck DL; Perdikis G; Rawal B; Bagaria S; McLaughlin SA
Ann Surg Oncol; 2014 Oct; 21(10):3297-303. PubMed ID: 25047470
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant taxanes in the treatment of breast cancer: no longer at the tip of the iceberg.
Dang C; Hudis C
Clin Breast Cancer; 2006 Apr; 7(1):51-8. PubMed ID: 16764744
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
14. Predictors of fatigue 30 days after completing anthracycline plus taxane adjuvant chemotherapy for breast cancer.
Wielgus KK; Berger AM; Hertzog M
Oncol Nurs Forum; 2009 Jan; 36(1):38-48. PubMed ID: 19136337
[TBL] [Abstract][Full Text] [Related]
15. [Influence of clinical and biographical factors on the quality of life of women with breast cancer receiving adjuvant chemotherapy].
Baena-Cañada JM; Estalella-Mendoza S; González-Guerrero M; Expósito-Álvarez I; Rosado-Varela P; Benítez-Rodríguez E
Rev Calid Asist; 2011; 26(5):299-305. PubMed ID: 21925913
[TBL] [Abstract][Full Text] [Related]
16. Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens.
Griggs JJ; Culakova E; Sorbero ME; Poniewierski MS; Wolff DA; Crawford J; Dale DC; Lyman GH
J Clin Oncol; 2007 Jun; 25(18):2522-7. PubMed ID: 17577029
[TBL] [Abstract][Full Text] [Related]
17. Improved survival for women with stage I breast cancer in south-east Sweden: a comparison between two time periods before and after increased use of adjuvant systemic therapy.
Johansson P; Fohlin H; Arnesson LG; Dufmats M; Nordenskjöld K; Nordenskjöld B; Stål O;
Acta Oncol; 2009; 48(4):504-13. PubMed ID: 19235568
[TBL] [Abstract][Full Text] [Related]
18. Effects of immediate reconstruction on adjuvant chemotherapy in breast cancer patients.
Eck DL; McLaughlin SA; Terkonda SP; Rawal B; Perdikis G
Ann Plast Surg; 2015 Jun; 74 Suppl 4():S201-3. PubMed ID: 25664417
[TBL] [Abstract][Full Text] [Related]
19. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.
Pivot X; Romieu G; Debled M; Pierga JY; Kerbrat P; Bachelot T; Lortholary A; Espié M; Fumoleau P; Serin D; Jacquin JP; Jouannaud C; Rios M; Abadie-Lacourtoisie S; Tubiana-Mathieu N; Cany L; Catala S; Khayat D; Pauporté I; Kramar A;
Lancet Oncol; 2013 Jul; 14(8):741-8. PubMed ID: 23764181
[TBL] [Abstract][Full Text] [Related]
20. Dose variation and regimen modification of adjuvant chemotherapy in daily practice affect survival of stage I-II and operable stage III Taiwanese breast cancer patients.
Kuo SH; Lien HC; You SL; Lu YS; Lin CH; Chen TZ; Huang CS
Breast; 2008 Dec; 17(6):646-53. PubMed ID: 18595699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
